{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:10Z","timestamp":1792670830469,"version":"4.5.0"},"reference-count":99,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Cardiol."],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.2217\/fca.15.31","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T13:37:27Z","timestamp":1435239447000},"page":"565-583","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Development of Rivaroxaban: Emerging New Clinical evidences?"],"prefix":"10.1080","volume":"11","author":[{"given":"Lu\u00eds","family":"Mont","sequence":"first","affiliation":[{"name":"Arrhythmia Section Institut del Torax Hospital Cl\u00ednic Universitat de Barcelona\rBarcelona\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Department of Cardiology Hospital Universitario Virgen de la Arrixaca Universidad de Murcia Instituto de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca IMIB-Arrixaca\rMurcia\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Garc\u00eda-Bragado","family":"Dalmau","sequence":"additional","affiliation":[{"name":"Internal Medicine Service Hospital Universitario Dr. Josep Trueta\rGirona\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianela S\u00e1nchez","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Cardiovascular Critical Unit Department of Cardiology. Hospital de la Santa Creu i Sant Pau\rBarcelona\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Gallego","family":"Cullere","sequence":"additional","affiliation":[{"name":"Neurology Department and Stroke Unit Complejo Hospitalario de Navarra\rPamplona\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,6,25]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0549-x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111096"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_3_2_13_1","unstructured":"European Medicines Agency (EMA) . Xarelto\u00ae \u201cSummary of Product Characteristics\u201d . Updated 08-October-2014 . www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1586\/erc.12.172"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2014.931223"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574884708666131111204658"},{"issue":"3","key":"e_1_3_2_17_1","first-page":"486","article-title":"Pharmacology and mechanisms of action of new oral anticoagulants","volume":"21","author":"Salem JE","year":"2014","unstructured":"Salem JE , SabouretP, Funck-BrentanoC, HulotJS . Pharmacology and mechanisms of action of new oral anticoagulants . Fundam. Clin. Pharmacol.21 ( 3\u20134 ), 486 \u2013 497 ( 2014 ).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S45644"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.03.005"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12054"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.5"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.668020"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160143"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.288"},{"issue":"4","key":"e_1_3_2_25_1","first-page":"756","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen AT","year":"2007","unstructured":"Cohen AT , AgnelliG, AndersonFAet al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality . Thromb. Haemost.98 ( 4 ), 756 \u2013 764 ( 2007 ).","journal-title":"Thromb. Haemost."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0162"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.91B5.21691"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-21"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.118"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S47385"},{"issue":"12","key":"e_1_3_2_31_1","first-page":"904","article-title":"Stroke prevention in atrial fibrillation \u2013 current standard of care and significant unmet medical need","volume":"61","author":"Vora A","year":"2013","unstructured":"Vora A , NarasimhanC . Stroke prevention in atrial fibrillation \u2013 current standard of care and significant unmet medical need . J. Assoc. Physicians India61 ( 12 ), 904 \u2013 906 ( 2013 ).","journal-title":"J. Assoc. Physicians India"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"issue":"1","key":"e_1_3_2_33_1","first-page":"25","article-title":"Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack","volume":"59","author":"Masju\u00e1n J","year":"2014","unstructured":"Masju\u00e1n J , \u00c1lvarez-Sab\u00ednJ, BlancoMet al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack . Rev. Neurol.59 ( 1 ), 25 \u2013 36 ( 2014 ).","journal-title":"Rev. Neurol."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.08.008"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr342"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70042-X"},{"issue":"21","key":"e_1_3_2_37_1","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial","volume":"126","author":"Halperin JL","year":"2012","unstructured":"Halperin JL , BloomgardenZ, HellkampAet al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial . Circulation126 ( 21 ), Abstracts A15544 ( 2012 ).","journal-title":"Circulation"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.000067"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht492"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005008"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht428"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000521"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0454"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-12-RG-109"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-12-RG-034"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-88-0001"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0899"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.07.021"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-1324"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441901"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.977546"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.025"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.062"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu367"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.1.61"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-4-200508160-00005"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr113"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"e_1_3_2_64_1","volume-title":"The 36th Annual Congress of the European Society of Cardiology (ESC)","author":"Verheugt FWA","year":"2014","unstructured":"Verheugt FWA , VranckxP, LindeboomW, KimSY, LeebeekFWG . A prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual antiplatelet therapy to support elective percutaneous coronary intervention. The X-PLORER trial . Presented at : The 36th Annual Congress of the European Society of Cardiology (ESC), Barcelona, Spain ; 30 August\u20133 September 2014 ( Abstract P5520 )."},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-4-200702200-00007"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.007240"},{"key":"e_1_3_2_68_1","unstructured":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) NAVIGATE ESUS trial: Cardiovascular OutcoMes for People Using Anticoagulation StrategieS . http:\/\/clinicaltrials.gov\/show\/NCT02313909"},{"key":"e_1_3_2_69_1","unstructured":"Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease. COMPASS trial: Cardiovascular OutcoMes for People Using Anticoagulation StrategieS . http:\/\/clinicaltrials.gov\/show\/NCT01776424"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2014.09.010"},{"key":"e_1_3_2_71_1","unstructured":"A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1) . http:\/\/clinicaltrials.gov\/show\/NCT02293395"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjsupp\/4.suppl_D.D50"},{"key":"e_1_3_2_73_1","unstructured":"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following Hospitalization for Heart Failure (COMMANDER HF) . http:\/\/clinicaltrials.gov\/show\/NCT01877915"},{"key":"e_1_3_2_74_1","unstructured":"Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE (Venous Thromboembolism) (Einstein Choice) . http:\/\/clinicaltrials.gov\/show\/NCT02064439"},{"key":"e_1_3_2_75_1","unstructured":"Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Junior) . http:\/\/clinicaltrials.gov\/show\/NCT01684423"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12519"},{"key":"e_1_3_2_77_1","unstructured":"A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER) . http:\/\/clinicaltrials.gov\/show\/NCT02111564"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu291"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-014-9924-9"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.01.014"},{"key":"e_1_3_2_81_1","unstructured":"Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial\/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (X-TRA): Xarelto\u00ae\u2013ThRombus Accelerated resolution . http:\/\/clinicaltrials.gov\/show\/NCT01839357"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S32957"},{"key":"e_1_3_2_83_1","unstructured":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59\u20137939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)- oPen-label randomized controlled multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention . http:\/\/clinicaltrials.gov\/show\/NCT01830543"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.1.68"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000034.pub2"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S30064"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-08-0666"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-12-16"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S63298"},{"key":"e_1_3_2_90_1","unstructured":"Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events (GARFIELD-VTE) . http:\/\/clinicaltrials.gov\/show\/NCT02155491"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.09.011"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.001"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.12.019"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.002"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.011777"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.04.005"},{"key":"e_1_3_2_97_1","unstructured":"Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial or LA Appendage Thrombus in Patients With Non-valvular Atrial Fibrillation or Atrial Flutter After Standard of Care Anticoagulant Therapy (CLOT-AF) . http:\/\/clinicaltrials.gov\/show\/NCT01928979"},{"key":"e_1_3_2_98_1","unstructured":"Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation (EXPAND) . http:\/\/clinicaltrials.gov\/show\/NCT02147444"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2015.987126"},{"key":"e_1_3_2_101_1","volume-title":"55th American Society of Hematology (ASH) Annual Meeting 2013","author":"Mark C","year":"2013","unstructured":"Mark C , VandanaM, MichaelKet al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet al.fa (PRT064445), An Antidote For Fxa Inhibitors . Presented at : 55th American Society of Hematology (ASH) Annual Meeting 2013 . New Orleans, LA, USA, 7\u201310 December 2013 ( Abstract )."}],"container-title":["Future Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fca.15.31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:36:54Z","timestamp":1715989014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fca.15.31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,25]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.2217\/fca.15.31"],"URL":"https:\/\/doi.org\/10.2217\/fca.15.31","relation":{},"ISSN":["1479-6678","1744-8298"],"issn-type":[{"value":"1479-6678","type":"print"},{"value":"1744-8298","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}